The Food and Drug Administration is expected to approve a drug with an extremely high price tag. The new drug, called Zolgensma, treats a genetic disease called spinal muscular atrophy and is expected to cost about $2 million. WBUR’s Carey Goldberg (@goldbergcarey) reports.
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org.